Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis

Why It Matters

Earlier, AI‑driven identification of PPF can shrink diagnostic delays, enabling timely therapy that may extend survival and reduce healthcare costs in a disease with a median five‑year life expectancy.

Key Takeaways

• e‑Lung flagged PPF risk up to 28 months before conventional diagnosis
• REVISE‑PPF validated AI quantification of ILD features on CT scans
• PROGRESS‑PPF will collect quantitative and qualitative real‑world data
• Partnership aligns AI imaging with Boehringer’s ILD drug portfolio

Pulse Analysis

Pulmonary fibrosis remains one of the most lethal interstitial lung diseases, with many patients receiving a diagnosis years after symptom onset. Traditional radiologic assessment relies heavily on specialist expertise, leading to variability and delayed treatment. AI‑driven tools like Brainomix e‑Lung promise to standardize image interpretation, automatically quantifying subtle changes across serial CT scans and flagging disease progression earlier than the human eye can detect. This technological shift addresses a critical gap in the care pathway, where earlier intervention can markedly improve survival and quality of life.

The recent REVISE‑PPF study, conducted at leading academic centers, demonstrated that e‑Lung could stratify patients at risk of progressive pulmonary fibrosis from baseline scans and identify radiologic evidence up to 28 months before clinicians made a formal diagnosis. These findings have convinced Boehringer Ingelheim, a major ILD therapeutic developer, to deepen its collaboration with Brainomix. The upcoming PROGRESS‑PPF trial will prospectively evaluate e‑Lung in routine clinical settings across the United States, gathering both quantitative outcomes and qualitative feedback from physicians and patients. By proving real‑world efficacy, the study aims to secure broader regulatory acceptance and integration into standard diagnostic algorithms.

If successful, the partnership could reshape the market dynamics for ILD treatment. Earlier detection enables patients to start Boehringer’s antifibrotic therapies sooner, potentially extending life expectancy and reducing costly hospitalizations. Moreover, AI‑enabled imaging may become a reimbursable diagnostic adjunct, driving adoption across community hospitals lacking specialized radiology expertise. For investors and industry observers, this collaboration signals a growing convergence of biotech and AI, where data‑rich diagnostics accelerate drug uptake and improve overall health‑system efficiency.